Clinical trials: Stage II Pancreatic Cancer
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Pancreatic Cancer
Perifosine in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally…
- Trial name
- NCT00053924
- Testing
- perifosine
- Where
- 3 sites in Canada
- Sponsor
- University Health Network, Toronto
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This randomized phase III trial is studying gemcitabine and bevacizumab to see how well they work compared to gemcitabine alone in treating patients with locally advanced or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00088894
- Testing
- gemcitabine hydrochloride, bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective when given alone or in combination with another…
- Trial name
- NCT00012220
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 259 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Phase 2 Study, BMS-986504
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
- Conditions
- Phase 2 Study, BMS-986504, MTAP-deleted Pancreatic Cancer
- Trial name
- NCT07283705
- Testing
- BMS-986504, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Identification of Biomarkers for Early Detection of Pancreatic Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897494
- Testing
- protein expression analysis, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Adenocarcinoma of the Pancreas
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
This is a single-institution, single-arm phase II trial of Durvalumab combined with Radiation Therapy (RT) for metastatic pancreatic cancer patients who have progressed through first-line chemotherapy.
- Trial name
- NCT03490760
- Testing
- Durvalumab, Radiation Therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Baptist Health South Florida
Pancreatic Cancer
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
This is an adaptive design study. During the first phase of the study, participants will be randomized in 2:1 ratio to receive either MNTX 450 milligrams (mg) once daily (QD) or placebo.
- Trial name
- NCT04083651
- Testing
- Methylnaltrexone bromide
- Where
- United States
- Sponsor
- Bausch Health Americas, Inc.
Pancreatic Ductal Adenocarcinoma
A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer
This I/II study will evaluate to see how safe and useful irreversible electroporation (also called NanoKnife) is in patients with locally advanced pancreatic cancer.
- Trial name
- NCT03257150
- Testing
- Irreversible Electroporation, NanoKnife System
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00004861
- Testing
- gemcitabine hydrochloride, tacedinaline
- Where
- 16 sites in United States, Canada
- Sponsor
- Pfizer
Pancreatic Cancer
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
The current trial will provide important data on the recurrence rates and patterns of failure using state of the art target agent, chemotherapy and proton beam technology for patients with Locally Advanced Pancreatic Cancer…
- Trial name
- NCT01683422
- Testing
- Proton, Gemcitabine, Erlotinib, Capecitabine, Proton Radiation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Loma Linda University
KRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7
Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
This phase II trial studies how well selumetinib sulfate works in treating patients with pancreatic cancer with Kirsten rat sarcoma (KRAS) G12R mutations that has spread from where it started to nearby tissue or lymph nodes or…
- Conditions
- KRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT03040986
- Testing
- Laboratory Biomarker Analysis, Selumetinib Sulfate
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer
Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
This phase II trial is studying how well giving radiation therapy together with oxaliplatin and fluorouracil followed by gemcitabine works in treating patients with locally advanced, unresectable pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00096070
- Testing
- radiation therapy, oxaliplatin, fluorouracil
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Renal Cell Cancer
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person.
- Conditions
- Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma
- Trial name
- NCT02830724
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Cancer, Nonresectable Pancreatic Cancer
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
To evaluate the safety and effectiveness of CG8020 and CG2505.
- Trial name
- NCT00245362
- Testing
- CG 8020 and CG 2505
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cell Genesys
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00735917
- Testing
- saracatinib, pharmacogenomic studies, pharmacological study
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
Cardiovascular diseases and cancers, the two leading causes of death in Canada, require cholesterol to sustain their progression.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, Metastatic Cancer
- Trial name
- NCT04862260
- Testing
- Cholesterol metabolism disruption
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- CHU de Quebec-Universite Laval
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Pain, Bladder Cancer
Study of D-Methadone in Patients With Chronic Pain
The purpose of this study is to determine the safest dose of d-methadone that can be given, without causing severe side effects in most patients with chronic pain.
- Conditions
- Pain, Bladder Cancer, Breast Cancer, CNS Cancer
- Trial name
- NCT00588640
- Testing
- d-Methadone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas.
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
- Trial name
- NCT03042780
- Testing
- FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.